A randomized, double-blind trial demonstrated that inhibition of the IL‐1β by 150 mg of canakinumab every 3 months significantly reduced the primary efficacy endpoint of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter [10]. Here, CRP is linked to myocardial infarction.